JO3544B1 - عامل علاجي للاختلال الوظيفي في الفص الجبهي - Google Patents
عامل علاجي للاختلال الوظيفي في الفص الجبهيInfo
- Publication number
- JO3544B1 JO3544B1 JOP/2016/0045A JOP20160045A JO3544B1 JO 3544 B1 JO3544 B1 JO 3544B1 JO P20160045 A JOP20160045 A JO P20160045A JO 3544 B1 JO3544 B1 JO 3544B1
- Authority
- JO
- Jordan
- Prior art keywords
- cognitive impairment
- disease
- frontal lobe
- dementia
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يتعلق الاختراع الحالي بتوفير عامل علاجي و/أو وقائي، على سبيل المثال، للخلل الوظيفي بالفص الجبهي (على سبيل المثلا، قصور إدراكي (على سبيل المثال، قصور إدراكي في مرض باركينسون، قصور إدراكي ناجم عن إجهاد مزن، الخرف بأجسام ليوي، شلل فوق النوى مترقي، الخرف الجبهي الصدغي وما شابه) وما شابه)، مرض جسم ليوي ( على سبيل المثال، قصور إدراكي في مرض باكينسون، مرض جسم ليوي منتشر، الخرف بأجسام ليوي، اضطراب حركي مرتبط بمرض جسم ليوي وما شابه) وما شابه، الذي يتضمن مركب ممثل بالصيغة (<span dir="LTR">I</span>) أو ملح مقبول صيدلانية منه في صورة مكون فعال.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055532 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3544B1 true JO3544B1 (ar) | 2020-07-05 |
Family
ID=56919157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2016/0045A JO3544B1 (ar) | 2015-03-19 | 2016-03-17 | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US20180042910A1 (ar) |
| EP (1) | EP3270923B1 (ar) |
| JP (1) | JP6869893B2 (ar) |
| KR (1) | KR20170129764A (ar) |
| CN (1) | CN107405341A (ar) |
| AR (1) | AR103972A1 (ar) |
| AU (1) | AU2016234211B2 (ar) |
| BR (1) | BR112017018165A2 (ar) |
| CA (1) | CA2978426A1 (ar) |
| CL (1) | CL2017002351A1 (ar) |
| CO (1) | CO2017008814A2 (ar) |
| CR (1) | CR20170405A (ar) |
| CY (1) | CY1124459T1 (ar) |
| DK (1) | DK3270923T3 (ar) |
| DO (1) | DOP2017000206A (ar) |
| EA (1) | EA032511B1 (ar) |
| EC (1) | ECSP17069712A (ar) |
| ES (1) | ES2884846T3 (ar) |
| GE (1) | GEP20197007B (ar) |
| HK (1) | HK1249059A1 (ar) |
| HR (1) | HRP20211340T1 (ar) |
| HU (1) | HUE055387T2 (ar) |
| IL (1) | IL254196A0 (ar) |
| JO (1) | JO3544B1 (ar) |
| LT (1) | LT3270923T (ar) |
| MX (1) | MX2017012020A (ar) |
| MY (1) | MY196076A (ar) |
| PE (1) | PE20171621A1 (ar) |
| PL (1) | PL3270923T3 (ar) |
| PT (1) | PT3270923T (ar) |
| RS (1) | RS62311B1 (ar) |
| SG (1) | SG11201707012YA (ar) |
| SI (1) | SI3270923T1 (ar) |
| SV (1) | SV2017005527A (ar) |
| TN (1) | TN2017000369A1 (ar) |
| TW (1) | TWI723012B (ar) |
| UA (1) | UA123578C2 (ar) |
| WO (1) | WO2016148308A1 (ar) |
| ZA (1) | ZA201706136B (ar) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113016719B (zh) * | 2019-12-24 | 2022-08-02 | 复旦大学附属华山医院 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE325610T1 (de) | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
| LT3002283T (lt) * | 2003-12-26 | 2017-09-11 | Kyowa Hakko Kirin Co., Ltd. | Tiazolo dariniai |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
-
2016
- 2016-03-17 JO JOP/2016/0045A patent/JO3544B1/ar active
- 2016-03-18 AU AU2016234211A patent/AU2016234211B2/en not_active Ceased
- 2016-03-18 CN CN201680012849.8A patent/CN107405341A/zh active Pending
- 2016-03-18 TW TW105108544A patent/TWI723012B/zh not_active IP Right Cessation
- 2016-03-18 PT PT167651355T patent/PT3270923T/pt unknown
- 2016-03-18 ES ES16765135T patent/ES2884846T3/es active Active
- 2016-03-18 LT LTEP16765135.5T patent/LT3270923T/lt unknown
- 2016-03-18 EP EP16765135.5A patent/EP3270923B1/en active Active
- 2016-03-18 WO PCT/JP2016/059788 patent/WO2016148308A1/en active Application Filing
- 2016-03-18 PL PL16765135T patent/PL3270923T3/pl unknown
- 2016-03-18 KR KR1020177026576A patent/KR20170129764A/ko not_active Application Discontinuation
- 2016-03-18 AR ARP160100730A patent/AR103972A1/es unknown
- 2016-03-18 UA UAA201709985A patent/UA123578C2/uk unknown
- 2016-03-18 PE PE2017001525A patent/PE20171621A1/es unknown
- 2016-03-18 GE GEAP201614604A patent/GEP20197007B/en unknown
- 2016-03-18 EA EA201792070A patent/EA032511B1/ru unknown
- 2016-03-18 TN TNP/2017/000369A patent/TN2017000369A1/en unknown
- 2016-03-18 BR BR112017018165A patent/BR112017018165A2/pt not_active Application Discontinuation
- 2016-03-18 US US15/558,240 patent/US20180042910A1/en not_active Abandoned
- 2016-03-18 HU HUE16765135A patent/HUE055387T2/hu unknown
- 2016-03-18 DK DK16765135.5T patent/DK3270923T3/da active
- 2016-03-18 CA CA2978426A patent/CA2978426A1/en not_active Abandoned
- 2016-03-18 MX MX2017012020A patent/MX2017012020A/es unknown
- 2016-03-18 RS RS20211061A patent/RS62311B1/sr unknown
- 2016-03-18 JP JP2017547186A patent/JP6869893B2/ja active Active
- 2016-03-18 SG SG11201707012YA patent/SG11201707012YA/en unknown
- 2016-03-18 CR CR20170405A patent/CR20170405A/es unknown
- 2016-03-18 SI SI201631316T patent/SI3270923T1/sl unknown
- 2016-03-18 MY MYPI2017703320A patent/MY196076A/en unknown
-
2017
- 2017-08-29 IL IL254196A patent/IL254196A0/en unknown
- 2017-08-29 CO CONC2017/0008814A patent/CO2017008814A2/es unknown
- 2017-08-29 SV SV2017005527A patent/SV2017005527A/es unknown
- 2017-09-08 ZA ZA2017/06136A patent/ZA201706136B/en unknown
- 2017-09-11 DO DO2017000206A patent/DOP2017000206A/es unknown
- 2017-09-15 CL CL2017002351A patent/CL2017002351A1/es unknown
- 2017-10-18 EC ECIEPI201769712A patent/ECSP17069712A/es unknown
-
2018
- 2018-07-11 HK HK18108966.3A patent/HK1249059A1/zh unknown
-
2021
- 2021-08-20 HR HRP20211340TT patent/HRP20211340T1/hr unknown
- 2021-08-25 CY CY20211100762T patent/CY1124459T1/el unknown
- 2021-09-03 US US17/466,772 patent/US20210393606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3638315A4 (en) | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
| IL269599B1 (en) | 11, 13- modified schistosoxins for pain treatment | |
| GEP20207167B (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| WO2018023072A3 (en) | Compounds and compositions and uses thereof | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| TN2016000489A1 (en) | Carboxamide derivatives. | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| CY1124459T1 (el) | Θεραπευτικος παραγοντας για δυσλειτουργια του μετωπιαιου λοβου | |
| MX2018014136A (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor. | |
| WO2018111795A3 (en) | Use of sgc stimulators for the treatment of esophageal motility disorders | |
| PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
| MY198328A (en) | Adamantylmethylamine Derivative and use Thereof as Pharmaceutical | |
| EP4335508A3 (en) | (+)-azasetron for use in the treatment of ear disorders | |
| MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
| JP2018508540A5 (ar) | ||
| EP2924024A3 (en) | Solid forms of lorcaserin hydrochloride | |
| PH12019501027A1 (en) | Therapeutic drug or prophylactic drug for diabetic nephropathy | |
| SG10201912846PA (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease |